Five scientific abstracts on Vertex's cystic fibrosis drugs were presented at the 45th Conference of the European Cystic Fibrosis Society (ECFS) held in Rotterdam, the Netherlands, on June 8-11, 2022.
The presented analysis of data collected in the US CF Foundation Patient Registry CFFPR covering more than
16 thousand in subjects treated with ivacaftor/tezacaftor/elexacaftor in the combination regimen with ivacaftor for an average of nine months, showed that such treatment under real conditions was associated with an improvement in l...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
